CoreWeave to Participate in the BofA Securities Global Technology Conference

LIVINGSTON, N.J.--(BUSINESS WIRE)-- CoreWeave, Inc. (Nasdaq: CRWV), The Essential Cloud for AI™, today announced that Nick Robbins, VP Corporate Development and Investor Relations, will present at the BofA Securities Global Technology Conference in San Francisco, CA. The discussion will begin at 10:40 a.m. Pacific Time on June 3rd.

A live webcast and replay of the presentations will be available on CoreWeave’s Investor Relations site at investors.coreweave.com.

Disclosure Information

CoreWeave uses its investor relations page (investors.coreweave.com), its X account (@CoreWeave), and its LinkedIn page (linkedin.com/company/coreweave/) to disclose material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor these channels, in addition to following CoreWeave's press releases, Securities and Exchange Commission (SEC) filings, public conference calls and public webcasts.

About CoreWeave, Inc.

CoreWeave is The Essential Cloud for AI™. Built for pioneers by pioneers, CoreWeave delivers a platform of technology, tools, and teams that enables innovators to move at the pace of innovation, building and scaling AI with confidence. Trusted by leading AI labs, startups, and global enterprises, CoreWeave serves as a force multiplier by combining superior infrastructure performance with deep technical expertise to accelerate breakthroughs. Established in 2017, CoreWeave completed its public listing on Nasdaq (CRWV) in March 2025. Learn more at www.coreweave.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260528278010/en/

Investor Relations contact:
[email protected] / https://investors.coreweave.com/

Media contact:
[email protected] / https://www.coreweave.com/about-us

Source: CoreWeave, Inc.

You May Also Be Interested In

• Ambiq prices upsized public offering at $78 per share
• Pattern set for preliminary inclusion in Russell 3000 and Russell 2000 indexes
• DiaMedica doses first patients in Phase 2 fetal growth restriction trial